Experience of Temozolomide Mono- and Combination Therapy in Advanced Neuroendocrine Tumors (NETs) in Russia Abstract #910

Introduction: Temozolomide (T) demonstrated promising activity in NETs in numerous phase 2 studies worldwide. But there is not enough data about its efficacy in the Russian population.
Aim(s): To evaluate efficacy and tolerability of T mono- and combination therapy in advanced NETs.
Materials and methods: Twenty-seven patients (pts) with advanced NETs (10 pancreatic NETs, seven GI NETs, three bronchial carcinoids, two kidney NETs, one mediastinal and three NETs without primary) were treated with T in monotherapy (five pts) or combination regimens, which included T+nitrosourea derivatives (10 pts), T+irinotecan (seven pts), T+capecitabine (four pts) and combination with cisplatin (one pt). Primary tumor site was resected in 14 patients. Most of the patients received long-acting octreotide. Ten pts were chemotherapy-naive. The median time from initial diagnosis till treatment initiation was seven months. The mean age was 57 years (26-78), 12 females, 15 males. Tumor differentiation was as follows: Grade 1 in one patient (3.7%), Grade 2 in 24 patients (89%) and Grade 3 in two patients (7.3%).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Alexander Kuzminov

To read results and conclusion, please login ...

Further abstracts you may be interested in

#62 Genome-wide DNA methylation profiling of pancreatic neuroendocrine tumors identifies distinct methylation profiles and differentially methylated gene promoter regions associated with low, medium and high grade tumors
Introduction: Integration of genetics and epigenetics has emerged as a powerful approach to studying cellular differentiation (Mikkelsen et al, 2009) and tumorigenesis (Shen et al, 2007). The study of DNA methylation is of particular importance in cancer, as causal involvement has been demonstrated and it is the most stable of all epigenetic modifications, making it a desirable marker for both early detection and treatment of tumors. Hypermethylation of CpG sites in gene promoter regions leads to decreased gene expression; if such a gene is a tumor suppressor, this leads to carcinogenesis. To date, there have been no studies of genome-wide DNA methylation profiling of NETs. This study sets out to determine the DNA methylation profiles of low, intermediate and high grade pancreatic NET liver metastases with the intention of identifying dysregulated biological pathways in the development of these tumors. A protocol for the analysis formalin-fixed paraffin embedded tissue (FFPE) has also been developed in order to study these tumors in significant numbers following this pilot study.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Christina Thirlwell
#248 Difficulties in Differential Diagnostics of Neuroendocrine Tumors
Introduction: Primary neuroendocrine tumors (NET) of soft tissues and soft tissue metastases are seen rarely and need differentiation from other types of tumors (as chemodecroma or paraganglioma).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Alla Markovich
#474 Difficulties in Diagnosis and Management of Neuroendocrine Tumors of the Head and Neck: A Case Report
Introduction: Primary neuroendocrine carcinomas (NEC) are uncommon head and neck malignancies. They present with a varied histopathologic spectrum in sinonasal and other subsites.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Alla Markovich
#659 Everolimus in Patients with Previously Treated Metastatic Neuroendocrine Tumors (NETs)
Introduction: Everolimus is the standard of care in well-differentiated NETs. Previous randomized trials included patients treated with a maximum of two lines of prior chemotherapy. We evaluated everolimus in heavily pretreated patients with NETs.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: Alexander Kuzminov
#1275 Aranoza in the Treatment of Metastatic Neuroendocrine Tumors (NETs): Single Institution Experience
Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: prof Vera Gorbunova